These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 10969792)

  • 1. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
    Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
    Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
    Reist CJ; Garg PK; Alston KL; Bigner DD; Zalutsky MR
    Cancer Res; 1996 Nov; 56(21):4970-7. PubMed ID: 8895752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
    Shankar S; Vaidyanathan G; Kuan CT; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2006 Jan; 33(1):101-10. PubMed ID: 16459265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies.
    Vaidyanathan G; Alston KL; Bigner DD; Zalutsky MR
    Bioconjug Chem; 2006; 17(4):1085-92. PubMed ID: 16848419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
    Reist CJ; Archer GE; Kurpad SN; Wikstrand CJ; Vaidyanathan G; Willingham MC; Moscatello DK; Wong AJ; Bigner DD; Zalutsky MR
    Cancer Res; 1995 Oct; 55(19):4375-82. PubMed ID: 7671250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.
    Shankar S; Vaidyanathan G; Affleck DJ; Peixoto K; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2004 Oct; 31(7):909-19. PubMed ID: 15464393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
    Reist CJ; Archer GE; Wikstrand CJ; Bigner DD; Zalutsky MR
    Cancer Res; 1997 Apr; 57(8):1510-5. PubMed ID: 9108453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
    Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
    Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR.
    Foulon CF; Welsh PC; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2001 Oct; 28(7):769-77. PubMed ID: 11578897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
    Wikstrand CJ; Hale LP; Batra SK; Hill ML; Humphrey PA; Kurpad SN; McLendon RE; Moscatello D; Pegram CN; Reist CJ
    Cancer Res; 1995 Jul; 55(14):3140-8. PubMed ID: 7606735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
    van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
    J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-succinimidyl 3-[(131)I]iodo-4-phosphonomethylbenzoate ([(131)I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs.
    Shankar S; Vaidyanathan G; Affleck D; Welsh PC; Zalutsky MR
    Bioconjug Chem; 2003; 14(2):331-41. PubMed ID: 12643743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.
    Wikstrand CJ; McLendon RE; Friedman AH; Bigner DD
    Cancer Res; 1997 Sep; 57(18):4130-40. PubMed ID: 9307304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.
    Stein R; Govindan SV; Mattes MJ; Shih LB; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3079s-3087s. PubMed ID: 10541347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved iodine radiolabels for monoclonal antibody therapy.
    Stein R; Govindan SV; Mattes MJ; Chen S; Reed L; Newsome G; McBride BJ; Griffiths GL; Hansen HJ; Goldenberg DM
    Cancer Res; 2003 Jan; 63(1):111-8. PubMed ID: 12517786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor.
    Bender H; Takahashi H; Adachi K; Belser P; Liang SH; Prewett M; Schrappe M; Sutter A; Rodeck U; Herlyn D
    Cancer Res; 1992 Jan; 52(1):121-6. PubMed ID: 1727372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate.
    Zalutsky MR; Noska MA; Colapinto EV; Garg PK; Bigner DD
    Cancer Res; 1989 Oct; 49(20):5543-9. PubMed ID: 2477144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies.
    Yang W; Wu G; Barth RF; Swindall MR; Bandyopadhyaya AK; Tjarks W; Tordoff K; Moeschberger M; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA; Wikstrand CJ
    Clin Cancer Res; 2008 Feb; 14(3):883-91. PubMed ID: 18245552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.
    Stein R; Goldenberg DM; Thorpe SR; Basu A; Mattes MJ
    Cancer Res; 1995 Jul; 55(14):3132-9. PubMed ID: 7606734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate.
    Vaidyanathan G; Affleck DJ; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2002 Jan; 29(1):1-11. PubMed ID: 11786270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.